Obesity Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report View Sample

Published: October 31, 2022 Report Code: GDGMDHC22366IDB-ST

Select Item

Obesity Pipeline Drugs Market Overview

Obesity is defined as having an excessive amount of body fat. Obesity increases the risk of diseases and health problems such as heart disease, diabetes, and high blood pressure. The predisposing factors include age, family history, smoking, lack of sleep, and certain medications.

The obesity pipeline drugs market research report provides comprehensive information on the therapeutics under development for obesity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases.

Key Targets Glucagon Like Peptide 1 Receptor

Glucagon Receptor

Gastric Inhibitory Polypeptide Receptor

Cannabinoid Receptor 1

Glucagon Like Peptide 1

Islet Amyloid Polypeptide
Key Mechanism of Actions  Glucagon Like Peptide 1 Receptor Agonist

Glucagon Receptor Agonist

Gastric Inhibitory Polypeptide Receptor Agonist

Glucagon Like Peptide 1 Activator

Melanocortin Receptor 4 Agonist

Islet Amyloid Polypeptide Activator

Calcitonin Receptor Agonist
Key Routes of Administration Oral

Subcutaneous

Parenteral

Intravenous

Topical

Nasal
Key Molecule Types Small Molecule

Synthetic Peptide

Peptide

Biologic

Recombinant Peptide

Fusion Protein
Leading Companies Novo Nordisk AS, Eli Lilly and Co, Gubra ApS, Omeros Corp, AstraZeneca Plc, Jenrin Discovery Inc, Sciwind Biosciences Co Ltd, and Yuhan Corp
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Obesity Pipeline Drugs Market Segmentation by Targets

The key targets of the Obesity pipeline drugs market are Glucagon Like Peptide 1 Receptor, Glucagon Receptor, Gastric Inhibitory Polypeptide Receptor, Cannabinoid Receptor 1, Glucagon Like Peptide 1, and Islet Amyloid Polypeptide.

Obesity Pipeline Drugs Market Analysis, by Targets, 2022 (%)

Obesity Pipeline Drugs Market Analysis, by Targets, 2022 (%)

Buy The Full Report for More Target Insights Into The Obesity Pipeline Drugs Market, Download A Free Report Sample

Obesity Pipeline Drugs Market Segmentation by Mechanism of Actions

The key mechanisms of action in the obesity pipeline drugs market are Glucagon Like Peptide 1 Receptor Agonist, Glucagon Receptor Agonist, Gastric Inhibitory Polypeptide Receptor Agonist, Glucagon Like Peptide 1 Activator, Melanocortin Receptor 4 Agonist, Islet Amyloid Polypeptide Activator, and Calcitonin Receptor Agonist.

 Obesity Pipeline Drugs Market Analysis, by Mechanisms of Action, 2022 (%)

 Obesity Pipeline Drugs Market Analysis, by Mechanisms of Action, 2022 (%)

Buy The Full Report for More MoA Insights Into The Obesity Pipeline Drugs Market, Download A Free Report Sample

Obesity Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Obesity pipeline drugs market are oral, subcutaneous, parenteral, intravenous, topical, and nasal.

Obesity Pipeline Drugs Market Analysis, by Routes of Administration, 2022 (%)

 Obesity Pipeline Drugs Market Analysis, by Routes of Administration, 2022 (%)

Buy The Full Report for More RoA Insights Into The Obesity Pipeline Drugs Market, Download A Free Report Sample

Obesity Pipeline Drugs Market Segmentation by Molecule Types

The key molecule types in the Obesity pipeline drugs market are small molecule, synthetic peptide, peptide, biologic, recombinant peptide, and fusion protein.

Obesity Pipeline Drugs Market Analysis, by Molecule Types, 2022 (%)

Obesity Pipeline Drugs Market Analysis, by Molecule Types, 2022 (%)

Buy The Full Report for More Molecule Type Insights Into The Obesity Pipeline Drugs Market, Download A Free Report Sample

Obesity Pipeline Drugs Market - Competitive Landscape

Some of the leading companies in the Obesity pipeline drugs market are Novo Nordisk AS, Eli Lilly and Co, Gubra ApS, Omeros Corp, AstraZeneca Plc, Jenrin Discovery Inc, Sciwind Biosciences Co Ltd, and Yuhan Corp.

AstraZeneca Plc: AstraZeneca Plc (AstraZeneca) is a biopharmaceutical company, which is focused on the discovery, production, and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal, and metabolic diseases, cancer, autoimmune, infection, and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals, and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors, and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

Obesity Pipeline Drugs Market Analysis, by Companies, 2022 (%)

Obesity Pipeline Drugs Market Analysis, by Companies, 2022 (%)

Buy The Full Report for More Companies Insights Into The Obesity Pipeline Drugs Market, Download A Free Report Sample

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Obesity (Metabolic Disorders).

  • The pipeline guide reviews pipeline therapeutics for Obesity (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Obesity (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Obesity (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Obesity (Metabolic Disorders)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Obesity (Metabolic Disorders).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Obesity (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

180 Life Sciences Corp
9 Meters Biopharma Inc
Aardvark Therapeutics Inc
Adare Pharma Solutions
Adipo Therapeutics LLC
Adocia SAS
Agentix Corp
AgeX Therapeutics Inc
Altamira Therapeutics Ltd
Altimmune Inc
Amgen Inc
Amogen Pharma Pvt Ltd
Anagenesis Biotechnologies SAS
Antag Therapeutics ApS
AntiCancer Inc
Aoxing Pharmaceutical Company Inc
Aphaia Pharma AG
Applied Molecular Transport Inc
AptamiR Therapeutics Inc
Aptorum Group Ltd
AstraZeneca Plc
August Therapeutics Inc
AULBIO Co Ltd
Autotac Bio Inc
Betagenon AB
BioRestorative Therapies Inc
Biozeus Pharmaceutical SA
Boehringer Ingelheim International GmbH
Braasch Biotech LLC
Bristol-Myers Squibb Co
Bullfrog AI Inc
Caliway Biopharmaceutics Co Ltd
Callitas Therapeutics Inc
Can-Fite BioPharma Ltd
Caregen Co Ltd
Carmot Therapeutics Inc
Cellivery Therapeutics Inc
Celloram Inc
Centeer BioTherapeutics Ltd Co
CinFina Pharma LLC
Circadian Therapeutics
CK Regeon Inc
Clayton Biotechnologies Inc
CohBar Inc
Corbus Pharmaceuticals Inc
Corcept Therapeutics Inc
Courage Therapeutics Inc
CURx Pharmaceuticals Inc
CVI Pharmaceuticals US Inc
Cyta Therapeutics Inc
D&D Pharmatech Co Ltd
Daewoong Pharmaceutical Co Ltd
Dale Biotech LLC
DD Therapeutics LLC
DiscoveryBiomed Inc
Dompe Farmaceutici SpA
Dongkook Pharmaceutical Co Ltd
Eccogene (Shanghai) Co Ltd
Efil Bioscience Inc
Elevian Inc
Eli Lilly and Co
Empros Pharma AB
EncuraGen Co Ltd
Energesis Pharmaceuticals Inc
Enspire Bio Inc
Enterin Inc
Enterobiome
Eolo Pharma
ePurines Inc
EraCal Therapeutics AG
ERX Pharmaceuticals Inc
Eternygen GmbH
FGH BioTech Inc
Gan & Lee Pharmaceuticals Co Ltd
Genexine Inc
Gila Therapeutics Inc
Glaceum Inc
Glucox Biotech AB
Gmax Biopharm LLC
GPER G-1 Development Group LLC
Guangzhou BeBetter Medicine Technology Co Ltd
Guangzhou Dazhou Biomedical Technology Co Ltd
Gubra ApS
Gusto Global LLC
HanAll Biopharma Co Ltd
Hangzhou Adamerck Pharmlabs Inc
Hangzhou Jiuyuan Gene Engineering Co Ltd
Hanmi Pharmaceuticals Co Ltd
HEC Pharma Co Ltd
Huadong Medicine Co Ltd
i2O Therapeutics Inc
Ildong Pharmaceutical Co Ltd
Immungenetics AG
ImmunoBiome Inc
Infusion Biosciences
Innovimmune Biotherapeutics Inc
Intarcia Therapeutics Inc
Inversago Pharma Inc
Japan Tobacco Inc
JD Bioscience Inc
Jenrin Discovery Inc
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd
Johnson & Johnson
Kallyope Inc
Kissei Pharmaceutical Co Ltd
KSbitugen Co Ltd
Kwang Dong Pharmaceutical Co Ltd
Landsteiner Genmed SL
Lead Discovery Center GmbH
LG Chem Ltd
Life Biosciences LLC
Lipidio Pharmaceuticals Inc
Lixte Biotechnology Holdings Inc
MAKScientific LLC
MD Healthcare Inc
MeiraGTx Holdings Plc
Merck & Co Inc
Moon (Guangzhou) Biological Technology Co Ltd
MThera Pharma Co Ltd
Nano Intelligent Biomedical Engineering Corp
NeonMind Biosciences Inc
NeuroNano Pharma Inc
NGM Biopharmaceuticals Inc
NIMIUM Therapeutics Inc
Nordic Bioscience AS
Novartis AG
NovMetaPharma Co Ltd
Novo Nordisk AS
Nubiyota LLC
NuSirt Biopharma Inc
ObeTherapy Biotechnology
Ochre Bio Ltd
Omeros Corp
OPKO Health Inc
Oramed Pharmaceuticals Inc
Orbit Discovery Ltd
Otsuka Pharmaceutical Co Ltd
Oxt Therapeutics Inc
Palatin Technologies Inc
PegBio Co Ltd
Pfizer Inc
PhageNova Bio Inc
Preveceutical Medical Inc
Primetime Life Sciences LLC
Protheragen Inc
Pylum Biosciences Inc
Qoracle Co Ltd
Ramino-Bio Ltd
Raziel Therapeutics
Regeneron Pharmaceuticals Inc
Remd Biotherapeutics Inc
Renova Therapeutics Inc
Repurpose.AI Inc
Resalis Therapeutics Srl
Reviva Pharmaceuticals Inc
Rhamnopharma Inc
Rhythm Pharmaceuticals Inc
Rivus Pharmaceuticals Inc
RosVivo Therapeutics Inc
Saniona AB
Sanofi
Scioto Biosciences Inc
Sciwind Biosciences Co Ltd
Scohia Pharma Inc
Senda Biosciences Inc
Shanghai Benemae Pharmaceutical Corp
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai Innogen Pharmaceutical Technology Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
Shionogi & Co Ltd
Sigrid Therapeutics AB
Siragen Pharmaceuticals Inc
Sirnaomics Ltd
SJT Molecular Research SL
SK Bioscience Ltd
Slate Bio Inc
Soleno Therapeutics Inc
Structure Therapeutics Inc
Sun Pharmaceutical Industries Ltd
Takeda Pharmaceutical Co Ltd
Techfields Pharma Co Ltd
Terns Pharmaceuticals Inc
The United Laboratories International Holdings Ltd
Trigemina Inc
Tryp Therapeutics Inc
Twinpigbiolab Co Ltd
Twist Bioscience Corp
UGISense AG
Uni-Bio Science Group Ltd
Versanis Bio Inc
Viking Therapeutics Inc
Virtici LLC
Vivus LLC
XL-protein GmbH
Youngene Therapeutics Co Ltd
YSOPIA Bioscience SA
Yuhan Corp
Zealand Pharma AS
Zhejiang Doer Biologics Corp
Zihipp Ltd
Zylem Biosciences Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Obesity – Overview

Obesity – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Obesity – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Obesity – Companies Involved in Therapeutics Development

Obesity – Drug Profiles

Obesity – Dormant Projects

Obesity – Discontinued Products

Obesity – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Rubella (German Measles), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Rubella (German Measles) – Pipeline by Amogen Pharma Pvt Ltd, 2022

Rubella (German Measles) – Pipeline by Beijing Minhai Biotechnology Co Ltd, 2022

Rubella (German Measles) – Pipeline by Daiichi Sankyo Co Ltd, 2022

Rubella (German Measles) – Pipeline by Enesi Pharma Ltd, 2022

Rubella (German Measles) – Pipeline by Indian Immunologicals Ltd, 2022

Rubella (German Measles) – Pipeline by Micron Biomedical Inc, 2022

Rubella (German Measles) – Pipeline by Sinovac Biotech Ltd, 2022

Rubella (German Measles) – Pipeline by Vaxxas Inc, 2022

Rubella (German Measles) – Pipeline by Zhongyianke Biotech Co Ltd, 2022

Rubella (German Measles) – Pipeline by Zydus Lifesciences Ltd, 2022

Rubella (German Measles) – Dormant Projects, 2022

Figures

List of Figures

Number of Products under Development for Rubella (German Measles), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Obesity Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Obesity Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Metabolic Disorders reports
Pharmaceuticals
New
HER2-Positive Breast Cancer Epidemiology Analysis and Forecast to 2033
$3,995 | May 2024
Pharmaceuticals
New
Pharma M&A Deals Q1 2024 - Top Themes - Thematic…
$995 | May 2024
Pharmaceuticals
New
Friedreich Ataxia (FRDA) Marketed and Pipeline Drugs Assessment, Clinical Trials…
$3,495 | April 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Obesity Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Obesity Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more